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the new antipsychotic users. The outcome was time to first foster care placement 
transition during a 180-day follow-up. Cox proportional hazard models estimated 
hazard ratios (HRs) associated with antipsychotic initiation, adjusting for demo-
graphic, clinical, and foster care characteristics. RESULTS: Comparing new users to 
propensity-score matched nonusers, there was no difference regarding average days 
to placement transition (109 versus 113 days). The proportion experiencing a foster 
care placement transition (37% versus 36%) during the follow-up. The HR was 1.1 (95% 
CI: 0.7-1.6). CONCLUSIONS: Youth initiating antipsychotics had no significant reduc-
tion in foster placement transitions within the 180-day follow-up. Although antipsy-
chotics are widely used for aggressive behaviors, a better understanding of clinical 
management of youth in foster care is needed to promote stable foster placement.
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OBJECTIVES: The investigation was undertaken to determine the treatment pat-
tern used in psychiatric patients and also to determine the symptoms, risk fac-
tors and clinical presentation of patients with psychiatric diseases. METHODS: 
The present observational study was carried out at a tertiary care psychiatry 
hospital in Warangal, India over a period of six months. Three hundred prescrip-
tions were collected and analyzed according to the recommendations of World 
Health Organization. RESULTS: It was found that schizophrenia (45%, n= 147) 
is the most common among the study population followed by depression (31%, 
n= 122). Dementia was the least detected (5%, n= 8) psychiatric condition. Among 
Schizophrenia patients, mostly were administered with lorazepam (n= 131). On the 
other hand, amisulpride was found to be administered in fewer patients. Among 
29 anxiety patients, lorazepam was found to be widely used and fluvoxamine, pro-
pranolol, trazodone and mirtazapine were used in fewer number. Among Dementia 
patients mostly used drug was donepezil (n= 13). CONCLUSIONS: The study revealed 
the anti-psychotic drug utilization pattern in a tertiary care hospital of Warangal city 
(an historic city of south India). Among the study population, dementia was the least 
detected case. Schizophrenia and anxiety patients were mostly administered with 
lorazepam and however, among dementia patients, mostly used drug was donepezil.
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OBJECTIVES: Atypical antipsychotics (AAP) are commonly used to treat off-
label conditions such as anxiety, depression, and post-traumatic stress disorder. 
Despite a black box warning in 2005, AAP still remain the second most common 
therapeutic class used for dementia. The objective of the study is to determine 
resource utilization (RU) and costs in patients using AAP to treat off-label condi-
tions. METHODS: A retrospective cross-sectional study was conducted using 2009 
Medical Expenditure Survey (MEPS) data. Study sample included individuals aged 
≥ 18 years with at least 2 claims for AAP identified from the Prescribed Medicines 
file. Indications were identified using ICD-9-CM and CCCODEX codes from the 
Medical Conditions file. Schizophrenia and bipolar disorder were categorized 
as FDA approved indications; all other indications were categorized as off-label 
use. RU and costs were obtained from the Full-Year Consolidated Files. RESULTS: 
N= 352 patients had at least 2 claims for AAP. 55.7% were off-label users with 
1,442 AAP claims. The most common off-label conditions were depressive disorder 
(29.89% of claims), neurotic disorders (15.40%) and general symptoms (13.80%). 
5.20% of the claims were for dementia. The typical off-label AAP user was female 
(60.20%), White (67.86%) with mean age 51.11+16.81 years (R: 18-85). Mean RU for 
off-label users was 14.61+16.79 (0-138) office-based provider visits, 1.41+3.94 (0-32) 
hospital-outpatient visits, 0.61+1.38 (0-12) ED visits, and 0.36+0.83 (0-4) inpatient 
discharges. The average total cost was $13,751.64 per person. For FDA approved 
users, mean RU was 17.77+26.73 (0-216) office-based provider visits, 2.51+11.83 
(0-123) hospital-outpatient visits, 0.71+1.22 (0-7) ED visits, and 0.39+0.84 (0-5) inpa-
tient discharges. The average total cost was $14,573.93 per person. CONCLUSIONS: 
Off-label prescribing of AAP is still a prevalent practice and needs to be monitored. 
Future research will compare RU and costs among patients prescribed and not 
prescribed AAP for off-label indications.
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OBJECTIVES: To describe and evaluate health resource use (HRU) of schizophrenia 
patients enrolled to JANSSEN CONNECT® (JC). METHODS: This is a multi-center, 
retrospective medical chart review of patients enrolled in JC, a comprehensive 
information and assistance program that supports patients after a healthcare 
professional has determined a Janssen long-acting injectable atypical antipsy-
chotic to be the most clinically appropriate treatment option.  Data collected 
included demographic and clinical characteristics, HRU, outpatient and injection 
appointments (missed and completed) and medication usage. The index date was 
defined as LAI initiation date where new users initiated LAI on/after JC enrollment 
while continuous users initiated LAI prior to enrollment.  Descriptive analysis 
was conducted to evaluate the demographic, clinical characteristics and HRU of 
JC enrollees at 6-month pre- and post-index periods. Comparative analysis on 
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OBJECTIVES: Approximately 4.1% of the U.S. adult population suffers from serious 
mental illness (SMI). Those dually eligible for Medicare and Medicaid suffer dispro-
portionately from SMI (~30%). Antipsychotic medications can significantly improve 
the lives of people with SMI, but can have a variety of adverse effects, which may 
be exacerbated by polypharmacy. Antipsychotic nonadherence is also problematic. 
The real-world observation of antipsychotic utilization patterns has been identi-
fied as a priority. We assessed utilization of antipsychotics and other psychotropic 
medications among dually-eligible adults with SMI, including calculations of adher-
ence, discontinuation, switching and polypharmacy. METHODS: The Medicare Part 
D Drug Event (PDE) file was used to identify Washington State dual-eligibles who 
filled an antipsychotic prescription in 2010. Twelve-month antipsychotic utilization 
rates were broken down by class (typical or atypical), and by medication. Adherence 
was measured using the proportion-of-days-covered methodology. For nonadher-
ent beneficiaries we distinguished between those who discontinued use and those 
who switched to another antipsychotic. Rates of antipsychotic polypharmacy in a 
given 30-day period, and antidepressant and mood-stabilizer utilization within the 
12-month observation period were estimated. RESULTS: There were 21,749 WA State 
dual-eligibles who filled an antipsychotic prescription in 2010. Over the 12-month 
observation period, 92% of the sample filled an atypical antipsychotic prescription 
(adherent= 61%, discontinued= 9%, switched= 30%), and 16% filled a typical antipsy-
chotic prescription (adherent= 50%, discontinued= 11%, switched= 39%). Of the 4,307 
duals who used more than one antipsychotic within a 30-day window, 91% used a 
maximum of two medications and only 9% used three or more. Finally, during the 
12-month observation period, 46% of duals filled an antidepressant prescription 
and 23% filled a mood-stabilizer prescription. CONCLUSIONS: This information is 
critical for policymakers looking to improve quality of care and reduce costs, given 
that individuals with SMI often avoid clinical trials and duals accumulate roughly 
$300 billion [2013 USD] in annual healthcare expenditures.
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BACKGROUND: Legal indications for the use of methylphenidate are restricted to 
children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Despite its 
defined therapeutic indications, there is a trend in non-prescribed methylphenidate 
off-label use by students and professionals to improve performance. New terms 
related to this trend: academic doping, nootropic, cosmetic neurology or smart 
pill. OBJECTIVES: To describe findings and consequences on methylphenidate’s off-
label use for cognitive enhancement in healthy individuals. METHODS: A systema-
tized search was conducted to retrieve the best scientific evidence on the subject 
available in English, Portuguese or Spanish. RESULTS: One review evaluated nine 
studies on the use of methylphenidate among healthy medical students. The preva-
lence was 16%, with no gender difference. However, there was a higher prevalence 
among those with had a low academic performance. Most students (65.2%) began 
using the drug after starting college. The use was seasonal throughout the year - 
periods close to exams or at the end of the semester were associated with a higher 
demand for the stimulant. There is little evidence in the literature about the effect 
of methylphenidate on the cognition of those without ADHD. There is no evidence 
that the drug increases memorization or associative learning, only that it makes 
people more alert, but with their selective attention capacity reduced. Some studies 
suggest that stimulants may interfere with neural mechanisms for the consolida-
tion of learning and long-term memory, which is a risk for intellectual performance. 
Also, methylphenidate increases heart rate and blood pressure, potentially more 
worrying in adults than children due to possible associations with other substances 
and reports of sudden deaths and side psychiatric effects. CONCLUSIONS: Although 
we currently live in a highly competitive environment, it’s important to adopt social 
interventions that focus on the misuse of methylphenidate, alerting the public and 
focusing on the consequences of its non-prescribed use.
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OBJECTIVES: Attention-deficit hyperactivity/disruptive behavior disorders (ADHD/
DBD) often lead to multiple placement transitions among youth in foster care. 
Increasingly, antipsychotic medications are used off-label to manage disruptive 
behaviors. There is limited evidence of the impact of antipsychotic management of 
ADHD/DBD on placement stability among fostered youth. This study is to investigate 
the association between antipsychotic initiation and time to first foster care place-
ment transition among antipsychotic users and propensity-score matched nonus-
ers. METHODS: All youth (n= 18,034) involved in foster care anytime from January 
1, 2010 through March 31, 2014 in one Mid-Atlantic state were identified. Data were 
from child welfare administrative records linked with Medicaid claims. The index date 
was identified by filling the first antipsychotic prescription in 2010-2013. New antip-
sychotic users were restricted to youth with (1) continuous foster care involvement 
180 days preceding and following the index date, (2) any diagnosis of ADHD, conduct 
disorder, oppositional defiant disorder, impulsive control, and (3) no antipsychotics 
180 days before the index date. Propensity-score matched nonusers were defined as 
youth with no antipsychotic use in 2010-2013 and met the same selection criteria as 
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OBJECTIVES: While some complementary and alternative medicine (CAM) modali-
ties are known to be effective in treating and/or managing anxiety and depres-
sion, relatively little is known about the patterns of CAM use among U.S. adults 
with moderate mental distress (MMD). We (1) examined whether the prevalence 
rates of CAM use varies by race/ethnicity in U.S. adults with MMD, and (2) assessed 
which socio-demographic and health-related factors are associated with CAM use 
among these racially/ethnically diverse groups. METHODS: We used data collected 
from 2012 National Health Interview Survey (NHIS), which represents non-insti-
tutionalized U.S. adults with MMD (n= 6,016 unweighted). Using a cross-sectional 
design with survey data analysis techniques, we conducted descriptive analyses for 
prevalence rates of CAM use and multivariate logistic regression analyses to predict 
CAM use. RESULTS: Among adults with MMD, the overall prevalence of past year 
CAM use was significantly different across racial/ethnic groups (P< 0.0001), with 
Asians (44.7%) and others (46.8%) having the highest prevalence rates. Blacks and 
Hispanics had prevalence rates of 24.3% and 30.7%, respectively, which were lower 
than non-Hispanic Whites (44.3%). When controlling for other relevant factors, being 
younger in age (18-64), being female, living in the West, having higher educational 
attainment, being employed, having more than four ambulatory care visits and 
functional limitations were significantly associated with higher odds of CAM use 
(P< 0.05). CONCLUSIONS: Racial/ethnic differences exist in CAM use among U.S. 
adults with MMD. We also observed factors associated with higher odds of such CAM 
use, such as age, gender, geographic location, employment status, frequent ambu-
latory care visits, and functional limitations. To improve patient-centered mental 
health care, which may include integration of CAM use, mental health professionals 
and researchers should acknowledge that racial/ethnic differences exist in CAM use. 
Further studies are needed to explore why such patterns exist, and consequently, 
affect racial/ethnic minorities’ mental health.
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OBJECTIVES: The objective of this study was to examine the impact of obesity 
on one’s physical and mental health, healthcare costs and satisfaction with their 
healthcare. We hypothesized that obese respondents would report worse physical 
and mental health, higher medical costs and poorer satisfaction with their health-
care than patients without a diagnosis of obesity. METHODS: A representative 
(U.S.) sample of 5,000 adults completed an online survey regarding their health 
and healthcare. We compared respondents who were previously diagnosed with 
obesity to those who were not. We conducted bivariate analyses and multivariate 
logistic regression to assess the relationship between obesity and the outcomes of 
interest. RESULTS: 12% (n= 609) of respondents reported having been diagnosed 
with obesity. In bivariate analysis obese respondents reported worse overall physical 
health (p< .00001) and mental health (p < .0001). Additionally, respondents with a 
diagnosis of obesity were more likely to screen positive (20.8% vs 12%) on the PHQ-2 
depression screener (p < . 05). While out of pocket costs were significantly higher 
in obese respondents (p < .05), non-obese respondents tended to report paying 
more for their health insurance premiums (p< .05). Obesity was also associated 
with having more comorbid conditions (2.7 vs 1.9 respectively; p < .0001). Levels of 
satisfaction with the health system, their healthcare plan and healthcare provider 
between the groups varied. Multivariate analyses controlling for potential confound-
ing factors, including comorbidities, as expected impacted these findings and will 
be presented. CONCLUSIONS: Obesity is a public health epidemic and contributes 
to poor health outcomes. As the U.S. healthcare delivery system moves toward 
population based health care approaches, more research among obese individuals 
is needed to better understand the association between obesity and poor outcomes 
but also the relationship with other independent predictors that can be modified 
or addressed to enhance the health of our nation.
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OBJECTIVES: Underuse of clozapine, an evidence-based practice, and overuse of 
non-clozapine antipsychotic polypharmacy (hereafter, antipsychotic polyphar-
macy), an unsupported practice to treat patients with schizophrenia may result in 
undesirable consequences. This study evaluated provider-level prevalence of clozap-
ine and antipsychotic polypharmacy prescribing and associated factors. METHODS: 
Using 2010-2012 data from Pennsylvania’s Medicaid we identified all providers who 
regularly prescribed antipsychotics to non-elderly adult patients with schizophrenia 
(defined as ≥ 10 patients/year). We characterized providers’ patients and payers 
(managed care vs. fee-for-service) using Medicaid data, and providers’ demographics 
using CMS’s NPI file. We measured provider-level share of patients with clozapine 
use and antipsychotic polypharmacy use per year. Antipsychotic polypharmacy was 
defined as more than 90 days’ concurrent use of ≥ 2 non-clozapine antipsychotics, 
with 32-day gap allowance. We used generalized estimating equations with a bino-
mial distribution and a logit link to examine clozapine and antipsychotic polyphar-
macy practices and associated patient- and provider-level factors. RESULTS: The 
analytic cohort included 632-650 prescribers per year. Provider-level clozapine and 
antipsychotic polypharmacy practices were relatively stable over time. In 2012, pro-
vider-level mean shares of patients with clozapine and antipsychotic polypharmacy 
use were 6.9% (range: 0%-88.9%) and 7.0% (range: 0%-45.2%), respectively. A sizable 
proportion of providers prescribed antipsychotic polypharmacy but not clozapine 
(e.g., 15.5% in 2012). High volume prescribers were much more likely to prescribe 
clozapine (OR = 1.43, p< 0.01) and antipsychotic polypharmacy (OR = 2.65, p< 0.01) 
matched JC and non-JC patients to evaluate effectiveness of the program is on-
going. RESULTS: A total of 102 JC patients were included (15 continuous users 
and 87 new users). The mean age was 41 years (SD=13), 63% were males, 64% 
were covered by Medicaid, or Medicare, or dually covered, 63% lived with family/
friends and 29%, 30% and 25% had comorbidity conditions of depression, anxiety 
and bipolar disorder, respectively.  In the pre-index period, 22% of JC patients had 
any use of inpatient hospitalization, emergency room (ER) or crisis stabilization 
unit (20%, 1% and 5%, respectively) and 77% had outpatient visits.  Pre-index oral 
atypical antipsychotics (73%) and antidepressants (59%) were commonly used.  In 
the post- index period, 18% of patients had any use of inpatient hospitalization, ER 
or crisis stabilization unit (15%, 2% and 3%, respectively) and 84% had outpatient 
visits. Post-index oral atypical antipsychotics and antidepressant use was 59% 
and 57%, respectively. CONCLUSIONS: Preliminary evidence shows numerically 
lower inpatient, ER and crisis unit utilization from pre- to post-index period among 
schizophrenia JC enrollees.
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OBJECTIVES: To explore medication use patterns, health-care resource utili-
zation and economic burden among patients with schizophrenia in Beijing, 
China. METHODS: A retrospective analysis was performed using the Beijing Urban 
Employee Basic Medical Insurance Database from January 1, 2011 to December 31, 
2013. Patients diagnosed with schizophrenia were identified using the International 
Classification of Disease 10th diagnosis codes F20, and the first diagnosis date in 
2012 was designated as the index date. Patients were required to be at least 18 years 
old, without any cancer and with 12-months continuous enrollment after the index 
date. Descriptive statistics were used to describe patient profiles, medication usage, 
health-care resource utilization and annual direct medical costs during the 1-year 
follow-up period. RESULTS: A total of 17,609 patients were included with mean 
(±SD) age of 52 (±15) years, 54% females and 94% with the baseline medical co-
morbidities. During the study follow-up, 75% received antipsychotic monotherapy 
and 84% were treated with atypical antipsychotics. The proportion of patients with 
schizophrenia-related hospitalization was 9.6%, with 1.2 (±0.5) hospitalizations per 
patient-year, 118 (±98) days of total length of hospitalization stay per patient-year, 
and a 21% re-admission rate. Those with any schizophrenia-related outpatient visit 
had 5.7 (±4.4) outpatient visits per patient-year, with 82% having at least 2 outpatient 
visits. The all-cause annual direct medical costs per patient were $2,668 (±3,511), 
while schizophrenia-related annual costs were $950 (±2,150). The costs per schizo-
phrenia-related hospitalization were $4,050 (±3,592), with 10% of costs attributable 
to antipsychotics and 81% to non-medication medical costs. CONCLUSIONS: In 
Beijing, patients diagnosed with schizophrenia had a low rate of schizophrenia-
related hospitalization, and a high rate of medical co-morbidities. Most patients 
received antipsychotic monotherapy and atypical antipsychotics. The economic 
burden associated with schizophrenia was considerable.
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OBJECTIVES: To investigate Internet addiction (IA) among the students of three 
major universities: Astana Medical University (Kazakhstan), Ukrainian Medical 
Stomatological Academy (Ukraine) and Tashkent Institute of Railway Transport 
Engineers (Uzbekistan). METHODS: Our study was based on a questionnaire, which 
included two sections: demographic part and a traditional K.Yang’s questionnaire. 
Problematic Internet Use (PIU) indices were calculated according to 4 scales: social 
comfort, loneliness, distraction, and impulsiveness. We used Student’s t-test, 
Spearmen’s rank correlation coefficient and Cronbach alpha coefficient. RESULTS: 
The majority of male and female students reported about using Internet five or more 
times a week. It was detected a statistically significant difference between men and 
women according to the latter type of activity, where females were more likely to use 
the Internet for entertainment than males (p< 0.05). Data showed statistically signifi-
cant differences among men. The same comparison among women did not find any 
significant differences. IA disorder can lead to «Dry eye» syndrome, carpal tunnel 
syndrome (6,8%), neuroses, backaches and neckaches among young people. One of 
four respondents noted that they had an experienced pain, numbness in hands and 
wrists. Almost half of the students complain that they are concerned about their 
eyesight. The high value of the Spearman rank correlation coefficient (ranging from 
0.91 to 0.99) testifies about the inverse association between the number of answers 
and their rank. CONCLUSIONS: When all results were compared, statistically sig-
nificant differences of the comparative characterization of PIU among students by 
gender did not found (p> 0.05). The null hypothesis, which has proved the lack of 
differences in indicators of addictive behavior among students, is not confirmed. 
We found higher PIU indices among Kazakhstani students in the category of Social 
Comfort, in comparison with the students from Uzbekistan, having high PIU indices 
in the category of Diminished Impulse Control.
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